5LABENZ J, PETERSEN K U, ROSCH W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [ J]. Aliment Pharmacol Ther,2003,17 (8) : 1015-1019.
6MIURA M. Enantioseleetive disposition of lansoprazole and rabeprazole in human plasma[ J ]. Yakugaku Zasshi,2006, 126(6) :395-402.
7KIM K A, KIM M J, PARK J Y, et al. Stereoselective me-tabolism of lansoprazole by human liver cytochrome P450 enzymes[J]. Drug Metab Dispos, 2003,31 (10) :1227- 1234.
8ISHIZAKI T, HORAI Y. Review article: eytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole [ J]. Aliment Pharmacol Ther, 1999, 13 ( Suppl 3) :27-36.
9MIURA M, KAGAYA H, TADA H, et al. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole [ J ]. Xenobiotica, 2006,36 ( 1 ) : 95-102.
10TRAN A, REY E, PONS G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children [ J ]. Clin Pharmacol Ther,2002,71 (5) :359-367.
